Governing AI-Assisted Inpatient Hypoglycemia Prevention in Viet Nam: Predictive Alerts, Timely Bedside Assessment and Recurrence Prevention

Governing AI-Assisted Inpatient Hypoglycemia Prevention in Viet Nam: Predictive Alerts, Timely Bedside Assessment and Recurrence Prevention

A patient with type 2 diabetes is admitted to the hospital with pneumonia. Insulin is prescribed to manage elevated blood glucose, but the patient's appetite declines during hospitalization. One morning, the patient eats very little breakfast after receiving insulin. Later, a nurse notices sweating, weakness, and increasing confusion. A bedside glucose measurement shows 58 mg/dL.

The hospital uses an artificial intelligence (AI) system designed to predict hypoglycemia, but no high-risk alert was generated before the event.

The absence of an AI warning does not change the need for immediate clinical attention. The nurse must assess the patient and initiate appropriate care under the hospital's hypoglycemia management protocol. Once the episode has been treated, the clinical team needs to understand why it happened and what should change to prevent another.

The insulin regimen may no longer match the patient's nutritional intake. Kidney function may have deteriorated, increasing susceptibility to hypoglycemia. A delayed meal, interrupted nutrition, or change in clinical condition may not have been recognized in time.

This situation illustrates an important distinction between predicting a clinical event and preventing patient harm.

AI may help identify hospitalized patients whose risk of hypoglycemia is increasing before a low glucose value is recorded. However, prediction cannot replace bedside assessment, glucose monitoring, timely treatment, or the clinical decisions needed to prevent recurrence.

For healthcare organizations in Viet Nam, responsible implementation requires a dependable process connecting risk identification, medication and nutrition review, professional response, and monitoring of patient outcomes.

The question is not simply whether AI can predict hypoglycemia. It is whether hospitals can use those predictions to improve care without delaying treatment, overlooking patients, or introducing new risks.

Why Inpatient Hypoglycemia Is a Patient-Safety Concern

Hypoglycemia is an important complication of hospital care, particularly among patients receiving insulin or other glucose-lowering medicines.

Its clinical presentation varies considerably. Some patients experience sweating, tremor, hunger, or palpitations. Others develop weakness, confusion, behavioral changes, seizures, or loss of consciousness. Symptoms can be difficult to recognize in patients who are sedated, critically ill, or unable to communicate.

Hypoglycemia may also occur without the usual warning symptoms, particularly in people with impaired awareness of hypoglycemia or a history of recurrent episodes.

Hospitalized patients face additional risks because their treatment, nutritional intake, and physiological condition may change rapidly.

An insulin regimen that was appropriate when a patient was eating normally may become unsuitable when appetite declines. A procedure may unexpectedly delay a meal. Enteral feeding may be interrupted while previously administered insulin continues to act. Changes in kidney function, corticosteroid treatment, or other medicines may also affect glucose regulation.

Not every inpatient episode is caused by diabetes treatment. Hypoglycemia can occur in people without diabetes, particularly in the setting of severe illness or other underlying conditions.

The American Diabetes Association (ADA) Standards of Care in Diabetes—2026 identifies inpatient hypoglycemia as an important safety concern. Hypoglycemia is associated with increased mortality, although this association does not establish that every adverse outcome is caused by the low glucose episode itself. In some patients, hypoglycemia may also reflect the severity of underlying illness.

This distinction matters when hospitals evaluate patient-safety performance. The objective is to prevent avoidable treatment-related harm while recognizing that some episodes occur in patients with complex or rapidly deteriorating conditions.

For AI-assisted systems, recognizing increased risk is only the beginning. The more important challenge is ensuring that healthcare professionals identify changes in the patient's condition, respond appropriately, and reduce the likelihood of further episodes.

Establishing Clinical Definitions Before Introducing AI

A hospital cannot reliably evaluate a hypoglycemia prediction system without first establishing how hypoglycemia is defined and measured.

The ADA Standards of Care in Diabetes—2026 distinguishes three levels of hypoglycemia.

Level 1 hypoglycemia refers to glucose concentrations below 70 mg/dL (3.9 mmol/L) but at least 54 mg/dL (3.0 mmol/L). This is an important alert level because glucose may decline further, and prompt attention is required.

Level 2 hypoglycemia refers to glucose concentrations below 54 mg/dL (3.0 mmol/L). It represents clinically significant biochemical hypoglycemia requiring immediate intervention.

Level 3 hypoglycemia is defined by the clinical event rather than a specific glucose concentration. It involves altered mental or physical functioning that requires assistance from another person for recovery.

The distinction between biochemical glucose levels and clinical severity is important.

In the opening scenario, a measured glucose concentration of 58 mg/dL falls within the biochemical range for Level 1 hypoglycemia. However, the patient's increasing confusion requires urgent assessment. If the episode involves altered functioning that requires another person's assistance for recovery, it may meet the clinical definition of Level 3 hypoglycemia despite the measured glucose remaining above 54 mg/dL.

These classifications should not be confused when evaluating events or reporting patient-safety outcomes.

Hospitals also need appropriate glycemic treatment goals.

For most critically ill adults with hyperglycemia, ADA 2026 recommends a glucose target of 140–180 mg/dL (7.8–10.0 mmol/L) after glucose-lowering treatment is initiated.

For most noncritically ill adults, the recommended target is 100–180 mg/dL (5.6–10.0 mmol/L), provided it can be achieved without significant hypoglycemia.

These recommendations are not fixed targets for every patient. Individual circumstances, including illness severity, nutritional status, treatment requirements, and hypoglycemia risk, remain important.

More intensive glucose control is not necessarily safer. In critically ill patients, overly aggressive glucose lowering can increase hypoglycemia risk without providing an appropriate balance of benefit and harm.

ADA recommendation 16.12 calls for healthcare systems to adopt a hypoglycemia management protocol, establish individualized plans for identification, treatment, and prevention, document inpatient episodes, and track events for quality improvement.

Recommendation 16.13 states that treatment plans should be reviewed and changed as necessary to prevent hypoglycemia and recurrence whenever a blood glucose value below 70 mg/dL is documented.

These recommendations provide a useful clinical foundation for evaluating AI-assisted prevention. AI may support recognition of risk and timely review, but it should not create a competing definition of hypoglycemia or alter established thresholds for clinical response.

Predictive AI Is Not the Same as Glucose Monitoring

Several technologies may support hospital glycemic management, but they perform different functions.

Point-of-care blood glucose testing measures glucose at a particular time and supports immediate bedside decisions. It is commonly used when hypoglycemia is suspected or when glucose measurements are needed to guide treatment.

Continuous glucose monitoring (CGM) provides repeated estimates of interstitial glucose and information about glucose trends. Depending on the device and configuration, it may generate alerts when glucose approaches or crosses a selected threshold.

An AI prediction model may instead analyze electronic health record data to estimate the probability that hypoglycemia will occur within a future period, such as the following 24 hours.

These activities should not be confused.

A conventional electronic alert generated when a measured glucose value falls below 70 mg/dL is not necessarily an AI application. Similarly, a CGM threshold alarm does not automatically represent machine-learning prediction.

An AI model may examine previous glucose measurements, administered insulin, laboratory results, nutritional information, and other clinical variables to estimate future risk.

That estimate is not a current glucose measurement.

A patient identified as high-risk may never develop hypoglycemia. Another patient classified as low-risk may still experience a serious episode. Neither prediction should be treated as a guarantee.

These limitations have immediate implications for clinical practice.

A high-risk prediction may justify reviewing treatment, monitoring, and nutritional plans. However, a low-risk classification must never be used to dismiss symptoms, ignore a measured low glucose value, or reduce clinically necessary monitoring.

Healthcare professionals should also understand what information they are viewing. A displayed value may represent measured blood glucose, an interstitial glucose estimate, or an AI-generated probability of a future event.

Confusing these outputs could lead to inappropriate clinical decisions.

The safest approach is to treat AI prediction as additional information that supports professional attention, not as a replacement for established monitoring or clinical assessment.

Why Hypoglycemia Prediction Is Difficult During Hospitalization

Hypoglycemia risk changes throughout a hospital admission. A patient's condition may deteriorate within hours, while information in the electronic record may remain incomplete or delayed.

An AI model may recognize that a patient has received insulin, has impaired kidney function, or has experienced previous hypoglycemia. These are clinically relevant signals.

However, the system may not know that a meal was delayed, that the patient consumed only a small portion of the prescribed diet, or that enteral feeding was unexpectedly interrupted.

Some of the most important risk factors are difficult to capture consistently.

An insulin prescription does not prove that insulin was administered. A dietary order does not establish how much food the patient consumed. A planned feeding schedule may differ from the nutrition actually delivered.

Laboratory results can also become outdated when a patient's condition changes rapidly.

These differences matter because predictions depend on the information available to the model at the time they are generated.

Kidney dysfunction may increase susceptibility to hypoglycemia during treatment with certain glucose-lowering medicines. A reduction in corticosteroid dosing may lower insulin requirements. Vomiting, poor oral intake, or interruption of enteral or parenteral nutrition may create a mismatch between insulin action and glucose availability.

The consequences may develop before the relevant information is entered into the electronic record or processed by the AI system.

Hospitals considering predictive AI should therefore examine whether the required data are available, reliable, and sufficiently current.

Information about actual medication administration, recent glucose measurements, nutritional intake, and changes in clinical condition may be more useful than older orders or incomplete documentation.

When these data are missing, the system's limitations should be explicit. Missing information must not automatically be interpreted as evidence that no risk factor exists.

This is relevant to Vietnamese hospitals where information may be distributed across laboratory systems, medication records, bedside monitoring devices, and narrative nursing documentation.

A technically sophisticated model cannot reliably compensate for clinically important information that was never captured.

Timely Bedside Assessment Must Remain the Priority

One of the greatest potential risks of AI-assisted hypoglycemia prediction is that clinicians might become less responsive to symptoms or measured glucose results when the system has not generated an alert.

A patient with symptoms suggestive of hypoglycemia requires prompt clinical assessment and an appropriate glucose measurement when available.

When hypoglycemia is confirmed, or when a suspected severe episode requires urgent intervention, healthcare professionals should follow the hospital's approved management protocol.

The appropriate response depends on the patient's clinical condition, including consciousness, ability to swallow safely, and available treatment resources.

A patient who cannot swallow safely should not receive oral treatment simply because oral carbohydrate is commonly used for conscious patients who can swallow. Appropriate emergency treatment and escalation are necessary.

The ADA 2026 hospital guidance supports standardized, nurse-initiated protocols for prompt management of blood glucose below 70 mg/dL.

Measurement reliability also matters.

A point-of-care glucose result that is unexpected or inconsistent with the patient's clinical condition may require repeat testing and laboratory confirmation. This can be important in an asymptomatic patient with an unexpectedly low reading or in circumstances that affect bedside measurement accuracy.

However, checking an uncertain result must not delay urgent treatment when the clinical situation requires immediate action.

The same principle applies to CGM.

ADA 2026 supports continuing personal CGM during hospitalization when clinically appropriate, provided adequate resources, staff training, and institutional protocols are available. Confirmatory point-of-care glucose testing remains recommended for insulin dosing decisions and hypoglycemia assessment.

CGM may help identify nocturnal, prolonged, or otherwise unrecognized episodes. Nevertheless, interstitial glucose measurements can differ from blood glucose during rapid changes, and device performance may be affected by clinical circumstances.

When CGM readings do not match the patient's symptoms, the discrepancy requires appropriate professional assessment.

AI-generated predictions provide another source of information, but they should never override reliable bedside findings or established emergency response procedures.

A hospital's ability to recognize and treat hypoglycemia must remain fully functional whether the AI system is available, unavailable, or incorrect.

Preventing Recurrence Requires Reviewing the Clinical Causes

Treating an acute episode addresses the immediate danger, but it does not necessarily correct the circumstances that caused the hypoglycemia.

Consider a patient who develops hypoglycemia after receiving insulin but eating only a small portion of a meal. Once the episode has been treated, the clinical team needs to review whether the insulin regimen remains appropriate for the patient's nutritional intake. Without that review, similar circumstances may lead to another episode.

Other patients may require reassessment of kidney function, recent medication changes, interrupted nutrition, glucose monitoring frequency, or the timing of insulin administration relative to meals.

An effective response should consider whether the episode resulted from a potentially preventable treatment-related problem, an unexpected change in condition, or severe underlying illness.

Different healthcare professionals contribute to this assessment.

Nurses may identify missed meals, feeding interruptions, symptoms, or inconsistencies between insulin administration and nutritional intake. Physicians and other authorized prescribers determine whether treatment changes are necessary.

Clinical pharmacists may assess medication-related factors, dosing concerns, and potential interactions. Dietitians and diabetes specialists can support nutritional planning and complex glycemic management when available.

These activities should be coordinated so that a low glucose value leads to appropriate review rather than simply another entry in the clinical record.

A particularly important safeguard concerns patients with type 1 diabetes.

The updated ADA–European Association for the Study of Diabetes (EASD) consensus report published in September 2026 reinforces the importance of maintaining appropriate insulin treatment to prevent diabetic ketoacidosis.

In patients with type 1 diabetes, basal insulin should not be automatically discontinued because an AI system predicts increased hypoglycemia risk.

Any adjustment requires professional assessment and a plan that balances hypoglycemia prevention with the continuing need for insulin.

This illustrates why an automated response focused on preventing one adverse outcome may introduce another serious risk.

The purpose of hypoglycemia prevention is not to reduce glucose-lowering treatment indiscriminately. It is to maintain safe overall glycemic management while addressing the factors that increase the likelihood of low glucose.

What the 2026 Evidence Shows About Predictive AI

Research published in 2026 provides evidence that AI models can identify patterns associated with future inpatient hypoglycemia. However, these findings need to be interpreted according to the outcomes studied and the limitations of the methods used.

A study by Momenzadeh and colleagues, published in npj Digital Medicine on June 11, 2026, developed and evaluated a real-time deep learning model using electronic health record data from 143,124 adult inpatient admissions across three hospitals in the United States.

The study included adults hospitalized for at least 24 hours who received at least one antihyperglycemic medicine.

The model used time-series information, including medicines, laboratory results, dietary orders, and recorded meal consumption, to predict whether a blood glucose value below 70 mg/dL would occur within the following 24 hours.

The researchers compared the model with alternative prediction methods and evaluated performance using several statistical measures.

At a decision threshold of 0.7, the best-performing model achieved an F1 score of approximately 0.30, precision of 0.23, and recall of 0.44. Its area under the precision-recall curve (AUPRC), summarizing performance across decision thresholds, was 0.23.

These results demonstrate predictive capability, but they also reveal important limitations.

At the evaluated threshold, many positive predictions were not followed by the specified hypoglycemia outcome. The model also failed to identify a substantial proportion of the outcomes it was designed to predict.

Precision and recall should be interpreted in relation to the study's prediction time points and outcome definition. They should not be converted directly into estimates of how many individual patients would benefit from intervention.

The researchers also conducted prospective daily validation using extracts from live electronic health records. Predictive performance remained relatively stable during this assessment, supporting the technical feasibility of generating predictions from routinely collected hospital information.

However, prospective model validation is not the same as a prospective clinical trial of an AI-assisted prevention program.

The study did not establish that using the predictions to guide care reduced hypoglycemia, severe events, mortality, or other patient harms.

The researchers also identified limitations related to incomplete electronic health record data, potentially missed transient glucose abnormalities between measurements, and the burden that unnecessary alerts might create.

The study disclosed patent applications relating to the prediction model. This disclosure does not invalidate the findings, but it is relevant when interpreting the research and considering the independence of evidence supporting future products.

A separate 2026 multicenter retrospective study by Zhang and colleagues, published in Frontiers in Endocrinology, developed an interpretable machine-learning model for predicting inpatient hypoglycemia among adults with type 1 diabetes at five Chinese tertiary hospitals.

The study included 1,498 patients and examined whether routinely available clinical information could support risk stratification.

Its findings provide additional evidence that machine-learning methods may distinguish patients with different observed risks of hypoglycemia.

However, the research involved a specific type 1 diabetes population and retrospective clinical records. Its results should not be generalized automatically to people with type 2 diabetes, critically ill populations, or hospitals with different treatment practices.

Neither study demonstrates that implementing an AI prediction system necessarily improves patient outcomes.

For healthcare organizations considering deployment, this distinction is important. A model may identify statistical patterns associated with future events without demonstrating that clinicians can respond to its predictions effectively or that implementation will reduce patient harm.

The available evidence supports further evaluation rather than assuming that predictive performance alone establishes clinical effectiveness.

The Vietnamese Clinical Context

Viet Nam has established professional guidance relevant to diabetes care.

Ministry of Health Decision No. 5481/QĐ-BYT, issued on December 30, 2020, introduced the professional guidance Diagnosis and Treatment of Type 2 Diabetes Mellitus. Decision No. 1353/QĐ-BYT, issued on February 23, 2021, amended and supplemented that guidance.

These documents provide an important national reference for managing type 2 diabetes, including considerations related to insulin treatment, hypoglycemia, and glycemic management during hospitalization.

However, they should not be interpreted as comprehensive national regulations covering every form of inpatient hypoglycemia or as a specific standard for AI-assisted risk prediction.

Hospitals must consider a wider patient population, including people with type 1 diabetes, critically ill patients, and those without diabetes who develop hypoglycemia during hospitalization.

Recent Vietnamese studies provide useful clinical context.

A study published in the Vietnam Journal of Community Medicine in July 2026 examined 1,098 patients admitted to a surgical intensive care unit at Viet Duc University Hospital between April 2024 and May 2025.

Thirty-three patients, representing approximately 3% of the study population, experienced at least one episode of hypoglycemia confirmed through venous blood glucose testing.

Among patients who developed hypoglycemia, many had severe underlying illness. Continuous renal replacement therapy was significantly associated with hypoglycemia in the study.

These findings illustrate the complexity of glucose management in critically ill patients. However, the research was conducted in a specific surgical intensive care setting, and its findings cannot be used to estimate the national incidence of inpatient hypoglycemia.

The observational design also does not establish that hypoglycemia directly caused adverse outcomes observed among patients with severe illness.

Another study, published online in the Journal of Diabetes and Endocrinology in April 2026, examined nocturnal hypoglycemia among 103 hospitalized patients receiving insulin at Hue Central Hospital.

The researchers reported nocturnal hypoglycemia in 12.6% of the study population.

This finding highlights the importance of recognizing episodes that occur outside routine daytime observation, particularly when insulin treatment and glucose monitoring require careful coordination overnight.

The study was relatively small and involved a different patient population and measurement approach from the Viet Duc study. The two percentages should therefore not be interpreted as directly comparable estimates.

Together, these studies illustrate why Vietnamese hospitals should understand their own patterns of hypoglycemia before adopting predictive technology.

A hospital's risk profile depends on its patient population, diabetes treatment practices, nutritional support, glucose monitoring procedures, and clinical resources.

Reliable baseline data may be more valuable at the beginning of an improvement program than immediately purchasing a prediction system.

Designing a Clinically Useful AI-Assisted Workflow

An AI-assisted hypoglycemia prevention system should be designed around a defined clinical purpose.

One possible application is identifying hospitalized adults receiving glucose-lowering treatment whose risk of hypoglycemia may increase within the following 24 hours.

A high-risk prediction could prompt the responsible clinical team to review recent glucose values, actual medication administration, nutritional intake, and important changes in clinical condition.

The expected response should be timely professional assessment rather than an automatic medication change.

The usefulness of the prediction depends partly on whether it reaches someone who can act.

An alert displayed on a separate dashboard may have little value if clinicians do not routinely use that interface. Similarly, a prediction delivered after a relevant medication has already been administered may offer limited opportunity for prevention.

Hospitals should determine who receives alerts, when they are reviewed, and what response is expected.

Nursing staff may be particularly well placed to recognize changes in food intake, symptoms, and bedside glucose results. Prescribers remain responsible for medication-order decisions within their professional scope, while pharmacists and diabetes specialists can contribute to medication and glycemic management review.

The workflow should distinguish preventive assessment from urgent treatment.

An AI prediction indicating increased risk during the following 24 hours may support timely care-plan review. A measured low glucose value or acute clinical deterioration requires an immediate response under the hospital's approved protocol.

The prediction system must not introduce another approval step before emergency care.

Meaningful documentation is also important. A prediction should not be considered successfully managed simply because a staff member acknowledges an alert electronically.

The clinical record should make it possible to determine whether the concern was reviewed, whether action was needed, and what decision was made.

At the same time, the system should avoid unnecessary documentation requirements that distract from bedside care.

Data Quality and Local Validation

An AI model that performs acceptably in a published study may not work reliably in every Vietnamese hospital.

The model may have been developed using electronic health records with different data structures, clinical terminology, monitoring practices, and medication workflows.

For example, laboratory glucose results may be available electronically while point-of-care measurements are recorded in another system. Insulin prescriptions may be structured, but actual administration times may be incomplete. Meal intake may appear in nursing notes rather than standardized electronic fields.

These differences affect the information available to the model.

Before implementation, the organization should determine whether the required inputs are available, accurate, clinically relevant, and sufficiently current.

The intended patient population must also be clearly defined.

A model developed using adults receiving antihyperglycemic medicines should not automatically be applied to children, pregnant patients, or people with hypoglycemia unrelated to diabetes treatment.

Similarly, a model developed in general medical wards may require additional evaluation before use in intensive care or other specialized settings.

Local validation should assess whether the system identifies the intended outcome reliably and whether predicted risks correspond reasonably to observed outcomes.

Performance should be evaluated at clinically meaningful alert thresholds.

Setting the threshold too low may generate large numbers of unnecessary alerts and increase workload. Setting it too high may cause the system to miss more patients who subsequently develop hypoglycemia.

There is no universally appropriate threshold. The decision should reflect local event frequency, the consequences of missed events, available staff resources, and whether preventive actions can realistically be taken.

Validation should also examine performance across clinically relevant groups, including older adults, patients with impaired kidney function, different diabetes types, and those with incomplete documentation.

Cases not flagged by AI must be included in the evaluation. Reviewing only high-risk predictions may conceal missed events and create a misleading impression of safety.

An initial silent evaluation may allow the system to generate predictions without affecting live clinical decisions. The outputs can then be compared with independently assessed outcomes while established care continues.

If performance is acceptable, a supervised clinical pilot may be considered. During the pilot, hospitals should monitor whether alerts lead to appropriate review, whether unnecessary notifications create additional workload, and whether unexpected safety problems emerge.

Substantial software updates, changes in laboratory systems, medication coding, or documentation practices may affect performance and require further evaluation.

Local validation is not a single technical exercise completed before launch. It should form part of continuing clinical oversight.

Measuring Prevention Rather Than Alert Activity

The number of AI alerts generated is not an adequate measure of patient safety.

A hospital needs to determine whether its intervention improves recognition, timely treatment, and prevention of recurrent hypoglycemia.

A reliable baseline is essential. The organization should understand how frequently hypoglycemia occurs, in which departments, among which patient groups, and under what clinical circumstances.

Definitions and denominators need to remain consistent.

Several low glucose measurements taken during the same episode should not necessarily be counted as separate events. Conversely, relying only on laboratory results may miss episodes identified through point-of-care testing or continuous monitoring.

Hospitals should establish an appropriate method for identifying distinct episodes and apply it consistently over time.

Relevant outcome measures may include Level 1 and Level 2 hypoglycemia rates, Level 3 events, recurrent episodes, and clinically important harm.

Depending on available data, event rates may be reported per 1,000 patient-days, as the proportion of eligible admissions affected, or through other clearly defined measures.

Interpretation should account for changes in monitoring frequency, patient characteristics, and clinical practice.

Process measures should examine whether documented low glucose values receive timely attention, whether the appropriate treatment protocol is followed, and whether the care plan is reviewed after an episode.

For AI-assisted workflows, additional measures may include the proportion of alerts receiving meaningful professional review, the time between prediction and clinical action, and the frequency of important missed predictions.

Balancing measures are equally necessary.

An intervention may increase alerts, glucose testing, nursing workload, or unnecessary treatment changes. Attempts to prevent hypoglycemia may also result in excessive hyperglycemia if insulin or other treatment is reduced inappropriately.

For patients with type 1 diabetes, monitoring should remain attentive to unsafe insulin interruption and the risk of diabetic ketoacidosis.

A reduction in hypoglycemia would not represent satisfactory improvement if it were accompanied by preventable deterioration in overall glycemic management.

Clinical outcomes should therefore be evaluated together rather than optimizing one measure at the expense of another.

Where feasible, hospitals should use an appropriate comparison design to distinguish the contribution of AI from improvements associated with staff education, revised protocols, or other changes introduced at the same time.

Learning From Missed Predictions and Recurrent Episodes

An effective hypoglycemia prevention program should examine why events occur despite existing safeguards.

When a patient experiences recurrent hypoglycemia, the clinical team should review the circumstances rather than simply record another low glucose value.

The review may identify a mismatch between insulin treatment and food intake, failure to reassess a changing clinical condition, delayed recognition, or incomplete communication between departments.

If AI was used, the organization should determine whether the model generated a prediction, whether it reached the appropriate staff, and whether a relevant clinical response followed.

A missed prediction may reflect incomplete information, delayed data, an unsuitable alert threshold, or limitations of the model itself.

A high-risk prediction that is not followed by hypoglycemia should not automatically be classified as clinically useless. The predicted episode may have been prevented through appropriate intervention, or the original prediction may have been incorrect.

Understanding the difference requires clinical review rather than reliance solely on automated performance statistics.

Hospitals should also examine whether the technology changes staff behavior.

If clinicians rely too heavily on AI classifications, they may become less responsive to important findings in patients labeled low-risk. Conversely, repeated alerts that rarely identify actionable concerns may contribute to alert fatigue.

Both situations can undermine patient safety.

Incident reviews should focus on identifying weaknesses in the overall process rather than using AI predictions to assign blame retrospectively.

The objective is to understand which safeguards worked, which were insufficient, and what changes could make prevention more reliable.

Legal and Professional Responsibilities in Viet Nam

AI-assisted inpatient hypoglycemia prevention must operate within Viet Nam's legal framework for medical examination and treatment, professional healthcare practice, artificial intelligence, medical devices, and personal data protection.

These frameworks address different responsibilities. Compliance with one does not automatically establish compliance with another or demonstrate that a particular clinical application is safe.

Professional Healthcare Responsibilities

The Law on Medical Examination and Treatment No. 15/2023/QH15, effective January 1, 2024, as subsequently amended, provides the broader legal foundation for professional healthcare practice, patient rights, medical records, and organizational responsibilities.

For patients with type 2 diabetes, Ministry of Health Decision No. 5481/QĐ-BYT, as amended by Decision No. 1353/QĐ-BYT, remains a relevant national professional reference.

Ministry of Health Circular No. 31/2021/TT-BYT, effective February 27, 2022, establishes requirements concerning nursing activities in hospitals, including patient assessment, nursing care, monitoring, and documentation within the relevant professional scope.

Healthcare organizations should ensure that locally approved protocols reflect applicable Vietnamese requirements and the clinical needs of their patient populations.

AI-generated predictions do not independently transfer responsibility for assessment, prescribing, medication administration, or emergency treatment from authorized healthcare professionals to software providers.

Organizations should establish who reviews alerts, makes treatment decisions, responds to urgent events, and evaluates recurrent hypoglycemia.

Artificial Intelligence Regulation

Viet Nam's Law on Artificial Intelligence No. 134/2025/QH15 took effect on March 1, 2026.

Decree No. 142/2026/NĐ-CP, effective May 1, 2026, provides implementing provisions, including those relating to AI risk classification and responsibilities of relevant parties.

Decision No. 33/2026/QĐ-TTg, effective August 15, 2026, establishes the List of High-Risk Artificial Intelligence Systems.

The healthcare-specific entries expressly identified in the list concern certain defined applications of AI-assisted surgery and robotic surgical systems. AI-assisted inpatient hypoglycemia prediction is not separately named among those healthcare entries.

However, the absence of a separately named application does not establish that every such system is legally low-risk, exempt from applicable obligations, or clinically safe.

The regulatory assessment depends on the system's intended purpose, actual functions, degree of automation, deployment arrangements, and relevant legal criteria.

A system that produces risk estimates for professional review may present different concerns from software that recommends treatment changes or automatically modifies insulin orders.

Healthcare organizations should assess the particular product and its intended workflow rather than relying on a general description of AI as a technology.

Clinical risk assessment must also consider the consequences of missed hypoglycemia, misleading predictions, inappropriate treatment changes, and delayed responses, regardless of statutory classification.

Medical Device Requirements

Some healthcare AI applications may fall within Viet Nam's medical device regulatory framework, depending on their intended medical purpose and functions.

Decree No. 98/2021/NĐ-CP on medical device management, as amended, provides part of the applicable framework.

Ministry of Health Circular No. 24/2026/TT-BYT, effective July 1, 2026, addresses risk determination and management measures for products classified as medical devices and amends relevant implementing provisions.

A product used only for administrative reporting may have a different intended purpose from software promoted to support medical prediction, diagnosis, or treatment decisions.

Similarly, a glucose monitoring device, an AI-based hypoglycemia prediction tool, and an automated insulin management system may raise different regulatory considerations.

The use of AI does not, by itself, determine medical device status. Product classification and related obligations must be assessed according to the specific intended use and applicable legal requirements.

Authorization or certification obtained in another jurisdiction may provide relevant evidence but does not automatically establish compliance with Vietnamese law.

Personal Data Protection and Information Governance

AI-assisted hypoglycemia prediction may involve identifiable information about diagnoses, medication orders and administration, laboratory results, nutritional intake, glucose measurements, and other aspects of the patient's clinical condition.

The Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/NĐ-CP, both effective January 1, 2026, provide relevant requirements concerning personal data processing and protection.

Healthcare organizations should establish the applicable lawful basis and purposes for processing, including relevant consent requirements or legally applicable exceptions.

Appropriate safeguards should address access permissions, information security, data retention, record traceability, and responsibilities involving external technology providers.

Particular attention is needed when identifiable patient information is hosted or processed by external AI services or transferred outside Viet Nam.

Hospitals should understand which data are used, how they are processed, where they are stored, who can access them, and whether technology providers may use them beyond the approved clinical purpose.

Information collected for patient care should not automatically be reused for commercial AI model development or training without assessing the applicable legal basis and required safeguards.

AI-generated predictions should also remain distinguishable from measured clinical information and authorized professional decisions.

These arrangements support both personal data protection and clinical accountability.

International guidance from ADA, EASD, and other professional organizations can inform Vietnamese clinical practice and quality improvement, but it does not automatically become binding Vietnamese law.

The proposed governance measures described in this article should be distinguished from mandatory legal obligations unless a specific applicable provision establishes such a requirement.

A Practical Starting Point for Vietnamese Hospitals

Hospitals considering AI-assisted hypoglycemia prevention should begin by examining their existing glycemic management processes.

A focused review of recent hypoglycemic episodes in one department can provide useful information about how events were identified, whether treatment was timely, and whether contributing factors were addressed.

The review may reveal weaknesses that do not require AI.

Delayed meals, inconsistent communication about feeding interruptions, incomplete glucose monitoring, or failure to reassess insulin treatment after a low glucose result may be addressed through clearer procedures, staff training, and improved coordination.

These improvements should not be postponed while the hospital evaluates predictive technology.

If AI appears likely to add value, the organization can define a limited initial use case, such as identifying adult inpatients receiving glucose-lowering treatment who may require additional assessment during the following 24 hours.

The intended population, prediction timeframe, available data, and expected clinical response should be specified before testing.

An initial silent evaluation may allow the model to generate predictions without influencing live treatment decisions. This enables the hospital to assess local performance, missed events, unnecessary alerts, and data processing reliability while established clinical care continues.

If performance is acceptable, the organization may proceed to a supervised clinical pilot.

During the pilot, AI predictions should support professional assessment rather than independently change insulin orders or determine emergency treatment.

The hospital should examine whether alerts lead to appropriate review, whether workload remains manageable, and whether clinical outcomes improve without new safety problems.

Findings should be reviewed through an established clinical quality and governance process, with authority to modify, restrict, suspend, or discontinue the AI function when necessary.

Expansion to additional departments should depend on demonstrated reliability and practical benefit.

A model evaluated in a general medical ward should not automatically be introduced into an intensive care unit, pediatric service, or another patient population without considering whether further evaluation is needed.

Throughout implementation, the hospital must preserve its ability to monitor glucose, recognize hypoglycemia, provide appropriate treatment, and prevent recurrence when AI is unavailable.

The purpose is to strengthen an existing patient-safety process, not make essential care dependent on a prediction system.

From Predictive Alerts to Safer Glycemic Care

AI-assisted inpatient hypoglycemia prediction offers an opportunity to recognize changing clinical risks and direct professional attention toward patients who may need additional assessment.

Research published in 2026 demonstrates that models can analyze routinely collected hospital information to estimate the likelihood of future low glucose values.

However, predictive capability is not the same as demonstrated clinical effectiveness.

For healthcare organizations in Viet Nam, safe implementation begins with reliable glucose monitoring, timely bedside assessment, established treatment protocols, and clear responsibility for reviewing the circumstances that contribute to recurrent hypoglycemia.

AI may help clinicians recognize a patient at increased risk before an episode occurs. That information becomes useful only when healthcare professionals can interpret it, assess the patient, and make appropriate decisions.

A patient who develops hypoglycemia despite a low-risk prediction still requires immediate care. A patient whose glucose recovers after treatment still needs an appropriate review of the factors that contributed to the episode.

Preventing hypoglycemia must remain part of safe overall glycemic management rather than becoming a reason to reduce necessary glucose-lowering treatment indiscriminately.

The success of an AI-assisted system should not be measured by how many patients it flags or how many alerts appear on a dashboard.

It should be judged by whether clinically important risks receive appropriate attention, preventable hypoglycemia is reduced, recurrence is addressed, and patient safety improves without introducing new harm.

AI may help identify when a patient needs attention. The responsibility for recognizing, treating, and preventing hypoglycemia remains with the healthcare team.

Selected References and Regulatory Sources

International Clinical Guidelines

American Diabetes Association Professional Practice Committee for Diabetes. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). DOI: 10.2337/dc26-S016.

American Diabetes Association Professional Practice Committee for Diabetes. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). DOI: 10.2337/dc26-S006.

Holt RIG, DeVries JH, Hess-Fischl A, et al. The Management of Type 1 Diabetes in Adults: The Updated 2026 Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. Published September 15, 2026. DOI: 10.2337/dci26-0122.

Clinical AI and Implementation Evidence

Momenzadeh A, Cranney C, Chen DH, Nguyen EV, Gianchandani R, Meyer JG. Development and Prospective Evaluation of a Real-Time Deep Learning Model for Inpatient Hypoglycemia Prediction. npj Digital Medicine. 2026;9:728. DOI: 10.1038/s41746-026-02874-1.

Zhang Q, Saad SH, Zhou H, et al. Development and Validation of an Interpretable Machine Learning Model for Predicting In-Hospital Hypoglycemia in Adults With Type 1 Diabetes Mellitus: A Multicenter Retrospective Study. Frontiers in Endocrinology. 2026;17:1816599. DOI: 10.3389/fendo.2026.1816599.

Vietnamese Clinical Guidance and Research

Ministry of Health of Viet Nam. Decision No. 5481/QĐ-BYT, dated December 30, 2020, issuing the professional guidance Diagnosis and Treatment of Type 2 Diabetes Mellitus (Hướng dẫn chẩn đoán và điều trị đái tháo đường típ 2).

Ministry of Health of Viet Nam. Decision No. 1353/QĐ-BYT, dated February 23, 2021, amending and supplementing Decision No. 5481/QĐ-BYT.

Nguyen Hai Ha Trang, Luu Quang Thuy, Nguyen Duy Gia, Nguyen Huu Hoang. Hypoglycemia and Associated Risk Factors in the Surgical Intensive Care Unit. Vietnam Journal of Community Medicine. 2026;67(7). DOI: 10.52163/yhc.v67i7.5943.

Nguyen IN, Tran TN, Nguyen THD, et al. Nocturnal Hypoglycemia in Insulin-Treated Patients With Diabetes Mellitus at Hue Central Hospital. Journal of Diabetes and Endocrinology. Published online April 29, 2026. DOI: 10.47122/VJDE.2025.82.6.

Relevant Vietnamese Legal and Regulatory Framework

National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15, effective January 1, 2024, as subsequently amended.

Ministry of Health of Viet Nam. Circular No. 31/2021/TT-BYT on Nursing Activities in Hospitals, effective February 27, 2022.

National Assembly of Viet Nam. Law on Artificial Intelligence No. 134/2025/QH15, effective March 1, 2026.

Government of Viet Nam. Decree No. 142/2026/NĐ-CP, detailing certain provisions and measures for implementing the Law on Artificial Intelligence, effective May 1, 2026.

Prime Minister of Viet Nam. Decision No. 33/2026/QĐ-TTg, promulgating the List of High-Risk Artificial Intelligence Systems, effective August 15, 2026.

Government of Viet Nam. Decree No. 98/2021/NĐ-CP on Medical Device Management, as amended.

Ministry of Health of Viet Nam. Circular No. 24/2026/TT-BYT on Risk Determination and Management Measures for Medical Devices and Amendments to Related Implementing Provisions, effective July 1, 2026.

National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15, effective January 1, 2026.

Government of Viet Nam. Decree No. 356/2025/NĐ-CP, detailing certain provisions and measures for implementing the Law on Personal Data Protection, effective January 1, 2026.

Editorial and Clinical Notice

This article is intended for professional education, responsible healthcare AI governance, and healthcare quality-improvement discussion. The opening clinical scenario is illustrative and does not describe an identified patient or documented clinical incident.

The article summarizes selected international clinical recommendations, published research, Vietnamese professional guidance, and relevant legal and regulatory considerations. It also describes proposed organizational approaches for AI-assisted risk identification, bedside assessment, hypoglycemia prevention, recurrence review, and performance monitoring.

These approaches do not constitute a mandatory Vietnamese AI implementation standard, an independently validated inpatient hypoglycemia prevention protocol, or a legal determination of any particular AI product's regulatory status.

The article does not provide patient-specific medical advice, authorize automated glucose-lowering medication adjustments, or replace professional clinical judgment.

Glucose monitoring, assessment, treatment of hypoglycemia, medication management, and prevention of recurrence must remain under the responsibility of appropriately qualified healthcare professionals, consistent with applicable Vietnamese requirements, current clinical guidance, and locally approved procedures.

AI predictions must not delay urgent clinical assessment or treatment. Predictive systems should not replace established glucose monitoring or be used to discontinue necessary insulin treatment without appropriate professional evaluation.

The evidence discussed does not establish that AI-assisted inpatient hypoglycemia prediction necessarily reduces severe hypoglycemia, recurrent events, mortality, or other adverse outcomes in Vietnamese healthcare settings. Local validation, supervised implementation, appropriate clinical oversight, and ongoing evaluation remain necessary before claims of clinical effectiveness can be made.

Digital Medicine Vietnam (DMVN) | Evidence and regulatory review: 1 November 2026.